Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-C2 shRNA
- Development stage
- Preclinical
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
MAGE-C2 shRNA is a short hairpin RNA (shRNA) therapeutic candidate designed to silence the expression of the Melanoma-associated antigen C2 (MAGE-C2) gene. MAGE-C2 is a member of the cancer-testis antigen family that is frequently overexpressed in multiple myeloma (MM) and is associated with aggressive disease and chemotherapy resistance. Delivered via a lentiviral vector in preclinical models, the shRNA mediates stable gene silencing of MAGE-C2, which triggers the DNA damage response pathway involving ATM/ATR and CHK1/CHK2 kinases. This activation leads to the stabilization of the p53 protein, resulting in cell cycle arrest at the G0/G1 and G2/M transitions and the induction of apoptosis through the upregulation of pro-apoptotic genes such as BAX and BAK. This agent is primarily utilized in research to investigate MAGE-C2 as a potential target for myeloma-specific therapies.
- Other names
- lentiviral MAGE-C2 shRNA
02
Targets
MAGEC2 (Melanoma-associated antigen C2)
Beyond the preview
Go deeper on MAGE-C2 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-C2 shRNA.